Topoisomerase inhibitors are in common use as chemotherapeutic agents although they can display reduced efficacy in chemotherapy-resistant tumours, which have inactivated DNA damage response (DDR) genes, such as ATM and TP53. Here, we characterise the cellular response to the dual-acting agent, Alchemix (ALX), which is a modified anthraquinone that functions as a topoisomerase inhibitor as well as an alkylating agent. We show that ALX induces a robust DDR at nano-molar concentrations and this is mediated primarily through ATR-and DNA-PK-but not ATM-dependent pathways, despite DNA double strand breaks being generated after prolonged exposure to the drug. Interestingly, exposure of epithelial tumour cell lines to ALX in vitro resulted in potent activation of the G2/M checkpoint, which after a prolonged arrest, was bypassed allowing cells to progress into mitosis where they ultimately died by mitotic catastrophe. We also observed effective killing of lymphoid tumour cell lines in vitro following exposure to ALX, although, in contrast, this tended to occur via activation of a p53-independent apoptotic pathway. Lastly, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo by demonstrating its ability to cause a significant reduction in tumour cell growth, irrespective of TP53 status, using a mouse leukaemia xenograft model. Taken together, these data demonstrate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents a novel anti-cancer agent that could be potentially used clinically to treat refractory or relapsed tumours, particularly those harbouring mutations in DDR genes.
INTRODUCTION
Topoisomerase (TOP) inhibitors are used as chemotherapeutic agents because of their potent ability to induce tumour cell death. [1] [2] [3] [4] Typically, TOP2 inhibitors fall into two classes depending on their target. 1, 5 The class I group (for example, etoposide, doxorubicin, mitoxantrone) affects the catalytic activity of TOP2 during the DNA cleavage/ligation reaction resulting in stabilisation of the TOP2 cleavage complex in the presence of unligated DNA double strand breaks (DSBs), ultimately triggering apoptosis. The second class inhibits the catalytic activity of TOP2 before cleavagecomplex formation and DSB generation and functions by reducing levels of chromosome-bound TOP2. As a consequence, since TOP2 is required to decatenate replicated DNA molecules before the onset of chromatid separation during mitosis, treatment with this type of TOP2 inhibitor (for example, aclarubicin) induces cell death by mitotic catastrophe due to anaphase-associated fragmentation of catenated chromatids. 6 While TOP2 inhibitors have been used relatively successfully as a mono-therapy, recently this approach has been largely superseded by combination therapies due to the ease with which tumour cells develop resistance. 7 Specifically, it has been shown that the acquisition of mutations in DNA damage response (DDR) genes, such as ATM and TP53, a reduction in the cellular pools of TOP2 protein or the overexpression of drug efflux pumps, are common underlying causes of tumours becoming refractory to TOP2 inhibitors. 8 Therefore, there is a clinical need for second-generation TOP2 inhibitors that can circumvent these mechanisms of drug resistance. Accordingly, a series of modified, anthraquinone-based compounds have been developed that combine the capability of class I TOP2 inhibitors to induce DSBs with the DNA damaging ability of alkylating agents. [9] [10] [11] The rationale for the development of these multi-functional DNA damaging agents is that they should induce genetic damage to such an extent that it cannot be tolerated even in the presence of mutations that compromise specific DNA repair, checkpoint or apoptotic pathways. Of these compounds Alchemix (ALX) was demonstrated to have the most potent anti-tumour activity in vivo using a xenograft mouse model. 9 Furthermore, ALX was not affected by overexpression of the multi-drug resistance gene P-gp, indicating that it may be a more effective chemotherapeutic agent for treatment of tumours that have developed resistance to noncovalent DNA binding anthraquinone-based drugs. Despite this, it is not known which DNA damage pathways are activated following ALX treatment and whether the inactivation of tumour suppressor genes that are important critical regulators of these pathways, such as ATM or TP53, could cause resistance. In this study we use a biochemical approach to determine the mode of action of ALX to ascertain whether it could be potentially used to clinically treat tumours that have developed resistance to conventional chemotherapeutic agents.
RESULTS

ALX induces a marked ATR-dependent DDR in tumour cells, independently of ATM and p53
To understand how ALX derives its potent anti-tumour activity we initially exposed HeLa cells to a range of concentrations of the drug and examined the activation of the DDR after 5 and 24 h, using Western blotting, coupled with antibodies recognising known substrates of the PI-3-kinase-like kinases, ATM and ATR. Phospho-ATM (S1981) was used a marker of ATM activation. Phospho-SMC1 (S966), Nbs1 (S343) and Chk1 (S345) were used as markers of cell cycle checkpoint activation. Lastly, phospho-RPA and γ-H2AX were used as markers of DNA damage. A dose of 10-100 nM elicited a significant response; therefore, 50 nM was used for most experiments ( Supplementary Figures S1A and B ). To confirm these observations and to determine whether p53 status affected the cellular response to ALX, several cancer lines (described in Supplementary Table S1 ) were treated with ALX (50 nM) and activation of DDR pathways was monitored. While the kinetics of DNA damage-induced signalling varied somewhat between the individual cell lines, we repeatedly observed strong activation of the DDR, suggesting that the anti-tumour activity of ALX is probably mediated through its ability to induce DNA damage (Figures 1a-c, Supplementary Figures S1C and D) .
Unlike other anthraquinone-based drugs, such as doxorubicin and mitoxantrone, which induce DNA damage by inhibiting TOP2, ALX can also damage cellular DNA through its alkylating side chain. 10 To determine which activity of ALX is more important for activating the DDR, we exposed HeLa cells to ALX or a derivative (ZP275) that cannot alkylate DNA while still retaining its ability to inhibit TOP2. Whereas both compounds could induce phosphorylation of known PI-3-kinase-like kinase substrates, loss of the alkylating side chain severely attenuated the DDR, indicating that it is a combination of these two DNA damaging properties that is important for ALX activity (Figure 1c ). Moreover, ALX treatment failed to induce the mono-ubiquitylation of PCNA (proliferating cell nuclear antigen), typically observed in cells exposed to compounds that alkylate DNA or agents that induce replication fork stalling (Supplementary Figure S2 ). This suggests that the mechanism underlying the DNA alkylation activity of ALX occurs in a manner distinct from other chemotherapeutics. and HeLa (c) cells were treated with ALX (50 nM) and harvested at the times shown. Protein phosphorylation was visualised by western blotting using the antibodies shown. HeLa cells (c) were also treated with the ALX derivative, ZP275, which fails to alkylate DNA, as shown.
In contrast to the signalling induced by ionising or ultraviolet radiation, the relative contribution of the individual PI-3-kinaselike kinases to activation of specific DDR pathways following exposure to class 1 TOP2 inhibitors is less well-understood. It has been previously reported that both ATM and ATR are activated in cells exposed to the TOP2 inhibitors etoposide or doxorubicin. 12, 13 This is clinically important since ATM is commonly mutated in many tumour types. One potential underlying reason for this is that these agents can induce both DNA DSBs as well as stalled replication forks, which activate ATM and ATR, respectively.
To ascertain whether ALX was capable of inducing DNA DSBs and activating an ATM-dependent DDR, HeLa cells were treated with ALX over 24 h. Cells were fixed and immunofluorescence microscopy was used to monitor DSB formation. Despite H2AX being strongly phosphorylated early in response to ALX treatment (2 h), only at later times (8-24 h) were γ-H2AX/53BP1 foci discernible, indicating that DSBs are only formed after prolonged exposure (Figures 2a and b ). This observation was supported by carrying out pulse-field gel electrophoresis on these cells following exposure to varying doses of ALX ( Figure 2c ). However, from our preliminary analysis of the DDR induced by ALX in tumour cell lines, the low level of ATM S1981 autophosphorylation suggested that, despite the ability of ALX to generate DSBs, ATM is not markedly activated (Figures 1a and b ). Consistent with this, ALX did not induce the phosphorylation of KAP1 or Chk2, two specific substrates of ATM (Supplementary Figure S3A ). Furthermore, combining the ATM inhibitor with ALX did not significantly affect activation of the DDR (Supplementary Figures S3B and S4A-C).
Since TOP2 inhibitors also induce replication-associated DNA damage, this would suggest that ATR could play a role in activating the damage-induced signalling pathways. To determine the contribution of ATR, DLD1 cells, engineered to mimic the human Seckel Syndrome-associated hypomorphic ATR mutation and its ATR complemented counterpart (Figure 3a ), were exposed to ALX and the DDR monitored. Consistent with a role for ATR in Figure 2 . DNA double strand breaks are generated only after prolonged exposure to ALX. (a) HeLa cells were exposed to ALX and processed for immunofluorescence microscopy at the indicated times post treatment. Cells were stained for γH2AX and 53BP1. Nuclear DNA was visualised with 4,6-diamidino-2-phenylindole (DAPI). (b) the proportion of γH2AX and 53BP1 foci (of various dimensions and intensities) formed was estimated on the basis of the representative images shown in the right-hand panel. The relative percentage of cells in each category at 24 h after ALX treatment is shown in the left-hand panel. The type V γ-H2AX/53BP1 staining pattern is typical of undamaged cells in S-phase. (c) Pulse-field gel electrophoresis was used to detect the presence of DNA double strand breaks (DSBs) in cells that were treated with increasing concentrations of ALX for 24 h. As a positive control for the presence of DSBs, cells were irradiated with 30 Gy of ionising radiation (IR) and harvested 2 h post irradiation.
controlling the DDR to ALX, compromising the level of ATR reduced phosphorylation of several DNA damage-regulated repair/checkpoint proteins, which was rescued by its re-expression ( Figure 3a ). Consistent with this, depletion of Claspin, a protein required for ATR-dependent Chk1 activation, reduced ATR-dependent phosphorylation of Chk1, induced by ALX (Supplementary Figure S5 ). These observations indicate that, unlike other DNA intercalating TOP2 inhibitors, ALX primarily elicits an ATR-but not ATM-dependent DDR, despite inducing DSBs.
Interestingly, the phosphorylation of H2AX and RPA2 in DLD1-Seckel cells was highly elevated following ALX treatment, compared with the complemented cells ( Figure 3a ). While ATR phosphorylates H2AX following exposure of cells to agents that stall replication forks, 14 it is likely that the observed enhanced phosphorylation of H2AX signifies the induction of replication stress, DSB formation and activation of a redundant PI-3-kinaselike kinase. Consistent with this, knock-in DLD1 cells in which an activation-associated serine residue of Chk1 was mutated to alanine (S317A) exhibited a similar exacerbated phosphorylation of H2AX/RPA2 response following exposure to ALX (Figure 3b ). This indicates that the ATR-Chk1 checkpoint pathway is not only required to signal activation of the DNA damage-induced intra-Sphase checkpoint, but is also essential for stalled replication fork stability. Treatment of DLD1-Seckel cells with ALX and an ATM inhibitor did not alleviate the induced replication stress, suggesting that in the absence of ATR, ATM is playing only a minor role in signalling pathways that are induced following ALX-dependent replication fork collapse (Figure 3d , Supplementary Figure S6A ). Based on this, it is likely that DNA-PK, which normally regulates repair of DSBs by NHEJ, also responds to DSBs induced during replication stress. It has been previously reported that DNA-PK undergoes auto-phosphorylation after the treatment of cells with genotoxic agents such as ultraviolet radiation, hydroxyurea and the TOP1 inhibitor, camptothecin. 15, 16 In addition, DNA-PK becomes rapidly activated following nucleotide depletion when Chk1 activity is compromised. 17 Consistent with this, we observed increasing DNA-PK activation following exposure of HeLa cells to ALX, suggesting that it may be involved in regulating the cellular response to this DNA damaging agent (Figure 3c ). To determine whether DNA-PK was responsible for the elevated phosphorylation of H2AX and RPA in ALX-treated DLD1-Seckel cells, we exposed these cells to ALX in the presence or absence of a DNA-PK inhibitor ( Figure 3d ). Strikingly, we observed that the H2AX and RPA2 phosphorylation induced by ALX in these cells was completely suppressed by the DNA-PK inhibitor, indicating that DNA-PK functions redundantly with ATR ( Figure 3d ). Surprisingly, we observed a modest reduction in the phosphorylation of Nbs1, Chk1 and RPA2 in cells treated with ALX and the DNA-PK inhibitor (Supplementary Figure S6B) , indicating that DNA-PK may also have a role in activating the cell cycle checkpoint pathway rather than just responding to replication-associated DSBs.
Taken together these data demonstrate that ALX induces a DDR primarily mediated by ATR and DNA-PK, which requires its ability to inhibit the TOP2 cleavage complex and to alkylate DNA. . ALX induces a DNA damage response mediated by ATR and DNA-PK. (a) DLD1-Seckel cells and DLD1-Seckel cells complemented with ATR were exposed to ALX (50 nM). Cells were harvested at the times shown. Protein phosphorylation was determined by western blotting using the antibodies shown. (b) Cells were treated as indicated in part (a) except that DLD1 cells in which Chk1 S 317 had been mutated to alanine were used. (c) HeLa cells were treated with ALX for the times shown. The phosphorylation of DNA-PK cs S 2056 was determined by western blotting. (d) DLD1-Seckel cells were treated with ALX for the times shown in the presence or absence of either the ATM inhibitor, KU60019, (10 μM) or DNA-PK inhibitor, NU7441, (10 μM). Protein phosphorylation was determined by western blotting using the antibodies shown.
ALX requires both TOP2α and TOP2β to elicit a DDR but not mismatch, Fanconi Anaemia or ubiquitin-dependent repair pathways To investigate which components of the damage response machinery, besides the ATR-Claspin-Chk1 replication-stress pathway, were important for eliciting a DDR following exposure to ALX, short interfering RNA (siRNA) and knockout cell lines were used. To ascertain if the DNA damage, particularly the DSBs, generated during ALX treatment largely depends on the presence of TOP2, cells were transfected with TOP2α-or TOP2β-directed siRNAs, exposed to ALX and the DDR examined ( Figure 4 ). Loss of either TOP2α or TOP2β alone failed to alleviate ALX-induced DNA DSBs, suggesting that ALX is probably capable of inhibiting multiple class II TOPs, not just TOP2α (Figure 4 ) as reported previously. 9 Consistent with this, siRNA-mediated knock down of both TOP2α and TOP2β reduced ALX-induced RPA2 phosphorylation (and that of H2AX to a limited extent), indicating that ALX is capable of targeting both forms of TOP2 in vivo ( Figure 4 ). However, knock down of TOP2α and/or TOP2β resulted in an elevated ATRdependent checkpoint response following ALX treatment (Figure 4 ), suggesting that events, independent of TOP2 inhibition, cause DNA lesions that largely determine its capacity to stall replication forks and activate ATR.
The mismatch repair (MMR) pathway has a key role in the response to DNA alkylating agents and is essential for activation of the ATR checkpoint pathway. 18, 19 As the ability of ALX to activate the ATR-dependent DDR requires its capacity to alkylate DNA, it is conceivable that this requires the MMR pathway. However, depletion of MSH2, critical to the MMR machinery, exacerbated rather than reduced the ALX-induced cellular DDR, demonstrating that the MMR pathway is dispensable for ALX-induced ATR activation (Supplementary Figure S7A ). This suggests that tumour cells with deficiencies in MMR could be hypersensitive to the killing effects of ALX as previously observed for other structurally related anthraquinone-based agents. 20, 21 To ascertain if the Fanconi Anaemia and the RNF8-dependent ubiquitin-dependent repair pathways, 21, 22 were involved in coordinating the cellular response to ALX, cells with or without FANCF or depleted of RNF8 were exposed to ALX and the damage response determined. Compromising either the Fanconi Anaemia or the RNF8-dependent ubiquitin-dependent repair pathways, 21, 22 did not affect the ALX-induced DDR significantly, suggesting that loss of these tumour suppressor pathways is unlikely to cause ALX resistance ( Supplementary Figures S7B and C ).
Exposure to low dose ALX leads to G2/M checkpoint arrest, checkpoint slippage-associated mitotic abnormalities and death by mitotic catastrophe Since TOP2 is critically involved in removing DNA supercoils resulting from DNA unwinding during replication and separating catenated sister chromatids prior to the onset of anaphase, it is likely that treating cells with ALX will have detrimental effects on their progress through both S-phase and mitosis. To determine how the kinetics of the DDR correlated with transit through the cell cycle, HeLa cells were exposed to a low dose of ALX and samples analysed by fluorescence-activated cell sorting (FACS) analysis. Consistent with the early activation of an ATR-dependent checkpoint response, cells treated with ALX for 4-8 h accumulated in S-phase (Figure 5a ). In keeping with the late induction of DSBs and subsequent activation of a DNA-PK-dependent DDR, cells treated with ALX for 24 h accumulated in late-S/G2-phase of the cell cycle as judged by the elevated levels of Cyclins A/B and low levels of phosphorylated histone H3 (Figures 5a and b) . However interestingly, a significant proportion of these cells bypassed the checkpoint and progressed into mitosis with unrepaired DNA damage, which resulted in the development of severe mitotic abnormalities, such as misaligned/fragmented chromosomes, anaphase-bridging and multi-polar spindles (Figure 5c ).
To determine whether the accumulation of DNA damage in cells entering mitosis contributes to cell death, HeLa cells were treated with higher doses of ALX and harvested every 24 h for analysis by FACS, western blotting and immunofluorescence microscopy. As a control, cells were also treated with cisplatin to induce cell death through classical apoptotic pathways. As expected, cisplatin induced cell death predominantly by apoptosis, as seen by PARP1 and Lamin B1 cleavage, proteolysis (activation) of Pro-caspase 3 and nuclear fragmentation ( Figures  6a and b) . In contrast, although higher concentrations (up to 0.5 μM) of ALX could induce a significant amount of cell death (Figure 6a ), this was not associated with markers of apoptosis or autophagy, (Figure 6b, Supplementary Figure S8A ), suggesting that these are not a major mode of cell death at these doses. A similar response was also seen in the p53 wt U2OS cell line as well as the p53-null H1299 cell line ( Supplementary Figures S8B  and C ). However, it should be noted that PARP1 was consistently observed to be cleaved to a limited extent at early times in some cell lines following ALX exposure (Figure 6b ). Despite this, we observed that ALX primarily induced cell death through a mechanism consistent with mitotic catastrophe/abortive mitosis, although a small proportion of the ALX-treated cells underwent apoptosis (Figures 6c and d) . Interestingly, cells undergoing prolonged mitotic arrest can trigger a partial apoptotic response and induce p53, following slippage into the next G1 phase of the cell cycle. 23 In this respect, exposure to ALX can lead to the stabilisation of p53, although its ability to upregulate downstream transcriptional targets, such as HDM2 and p21, appeared to be limited to later times following drug treatment, which coincided with the formation of DSBs and the appearance of abnormal mitotic cells (Supplementary Figure S8D ). This could, in part, explain the apoptotic-like cell death we observed in cells expressing wt p53 following exposure to a very high dose (41 μM) of ALX (Figure 7c, Supplementary Figure S9C ). Induction of DNA damage and cell death following exposure to ALX is enhanced in cycling cells and can be exacerbated under conditions of replication stress Given that the primary DDR response following ALX treatment requires ATR and that ALX-induced loss of cell viability is predominantly mediated through mitotic catastrophe, this suggests that cycling cells would be predicted to be more responsive to ALX. To test this, immortalised RPE1 cells were synchronised in G0/G1 by serum starvation or left to cycle asynchronously, treated with ALX and the DDR examined. Consistent with a cell cycle-dependency for ALX to induce a DDR, cells arrested in G0/G1 exhibited a highly attenuated ATR-dependent DDR, with the expression of a number of the key regulatory effector molecules, such as Chk1, being downregulated (Figure 7a ). Consequently the arrested cells demonstrated an increased resistance to the killing effects of ALX ( Figures  7b and c) . Again, as noted above, only at very high doses of ALX was cleavage of PARP1 and Lamin B1 observed.
It has been previously shown that pre-malignant cells commonly exhibit uncontrolled DNA replication that gives rise to elevated levels of DNA damage, which needs to be bypassed before tumourigenesis can progress. This has been termed 'replication stress'. While a number of genetic and epigenetic factors have been implicated in inducing replication stress, the most closely studied of these is the activation of certain oncogenes. Overexpression of Cyclin E, commonly associated with many tumours, causes an increase in replication fork stalling and DSBs. 24, 25 Since this hallmark of pre-malignant cells mildly mimics the cellular response to ALX we considered whether treatment of replication-stressed cells with ALX may exacerbate the cellular DDR. U2OS cells with either normal or significantly elevated levels of Cyclin E were exposed to ALX and the DDR monitored. Cells overexpressing Cyclin E exhibited an increased DDR, particularly the phosphorylation of RPA2 and H2AX, which coincided with the earlier generation of DSBs as judged by 53BP1 foci formation (Figures 8a and b) . A similar exacerbation of the DDR was also observed when immortalised human fibroblasts were infected with a recombinant adenovirus expressing Cyclin E or induced to overexpress mutant H-Ras G12V and then exposed to ALX ( Supplementary Figures S9A and B) . Moreover, the increased replication stress induced by Cyclin E overexpression in U2OS cells resulted in an earlier onset of an apoptotic-like cell death following exposure to a very high dose of ALX (Supplementary Figure S9C ). This supports the idea that ALX may have some specificity towards tumour cells with deregulated DNA replication and high levels of replication stress.
ALX exhibits therapeutic potential against lymphoid tumours irrespective of TP53 status in vitro and in vivo Resistance to treatment is a feature of subsets of most tumour types and, in the case of lymphoid tumours, such as B-and T-cell acute lymphoblastic leukaemia (T-ALL), is frequently associated with mutations in DDR genes such as ATM and TP53 or the upregulation of multi-drug resistance gene expression. [26] [27] [28] While chemo-resistance is evident in some treatment-naive tumours, genetic changes associated with chemotherapy resistance are frequently acquired during prolonged exposure to cytotoxic agents. 29, 30 In ALL, around 10% of paediatric patients and over 50% of adult patients fail to undergo complete remission or experience relapse following treatment. As mutations in TP53 has a major role in high risk and relapsed ALL disease, [30] [31] [32] ALX might represent a useful therapeutic approach for these tumours.
To investigate this, we tested the efficacy of ALX in vivo against primary and immortalised tumour cells with different p53 status (Figure 9a ). These included a primary paediatric T-ALL sample (BCH-505) and the Molt4 T-ALL cell line, both of which have wt TP53, and the TP53 mutant T-ALL cell lines CCRF-CEM and Jurkat. The primary T-ALL BCH-505 was engrafted into NOG mice, such that cells disseminated to the lymphoid organs within 4 weeks. The T-ALL tumour cell lines were injected subcutaneously to enable analysis of visible tumours. Following two doses of ALX, we observed a marked reduction in subcutaneous tumour size for the cell lines as well as the spleen weights (an indicator of tumour engraftment) and human CD45 tumour load in the primary T-ALL BCH-505-treated animals (Figures 9b and c) . This indicates no apparent difference in the sensitivities of the TP53 wt and mutant tumours to ALX in vivo.
To confirm the mechanism of killing, Western blotting was employed to establish that ALX induced a DDR in the T-ALL cell lines (Figure 9a ). Significant cell death was observed in all ALL cell lines in response to low dose ALX (summarised in Supplementary  Table S2 ) with considerable activation of apoptotic pathways as judged by the rapid cleavage of PARP1, Lamin B1 and Pro-caspase 3 as shown in Supplementary Figure S10 . This indicates that ALX can induce tumour cell death through multiple different pathways depending on the cell type treated and the dose used.
DISCUSSION
Most current empirically-based chemotherapeutic agents kill tumour cells by inducing irreparable genomic damage, leading to apoptosis. However, even complex and intensive combinations of cytotoxic agents fail to overcome the evolution and selection of treatment-induced sub-clones in some tumours, which leads to the outgrowth of refractory disease. 29, 30, 34, 35 Such sub-clones frequently arise following mutations in mediators of DNA damageinduced cell death, such as TP53. One major problem in combating treatment resistance is that our understanding of the mechanism of action of many chemotherapeutic agents currently used is limited.
Here, we demonstrate that ALX can induce a two-stage DDR that requires its ability to inhibit TOP2 and to alkylate DNA. Treatment of tumour lines with ALX induces replication damage, which in turn activates an ATR-dependent DDR and culminates in cells accumulating in G2-phase. It is likely that enzymatic processing or spontaneous collapse of stalled/aberrant replication forks results in the generation of DNA DSBs that triggers DNA-PK Figure 9 . The effect of ALX on leukaemic cells in vitro and in vivo. (a) ALX induces a DNA damage response in T-ALL cell lines. Jurkat, CEM and MOLT4 cells were treated with ALX (50 nM) and harvested at the times shown. Western blotting of lysates with the antibodies shown was used to visualise protein phosphorylation. (b) ALX reduces the tumour load in mice with tumours derived from T-ALL cell lines. Cells were injected into NOG mice, which were then treated (as indicated by arrows) with vehicle or ALX (5 mg/kg) as described. Tumour volume was measured. (c) ALX reduces tumour load in mice engrafted with paediatric T-ALL cells, BCH-505. The histograms show the relative size of the spleens in mice treated with ALX or controls at the time of death as well as the expression of human CD45 (*P ⩽0.05; **P ⩽ 0.005, ***P ⩽ 0.0005).
activation (summarised in Figure 10 ). This DDR can be initiated in the absence of known tumour suppressor genes, such as ATM, TP53, FANCF and MSH2, the mutation of which have been associated with treatment resistance. Moreover, despite a requirement for ATR and Chk1 to mediate activation of the ALXinduced cell cycle checkpoint, loss of this pathway exacerbates the formation of DSBs, indicating a role for ATR in preventing stalled replication fork collapse caused by exposure to ALX.
The DNA damage induced by ALX requires the presence of TOP2. However, in contrast to previously published data indicating that ALX specifically inhibits TOP2α, the depletion of both TOP2 isoforms was required to reduce ALX-induced phosphorylation of H2AX. Based on this observation, it is conceivable that resistance to ALX could develop by reducing cellular pools of TOP2α and β. Interestingly however, depletion of TOP2α and β does not affect activation of the ATR-dependent checkpoint response following exposure to ALX, indicating that suppression of cell replication and division could still be achieved with reduced TOP2 expression. Therefore, it is tempting to speculate that this is dependent upon its DNA alkylation function, which we have demonstrated is important for the ability of ALX to induce a DDR.
Given the complex nature of ALX's ability to produce a variety of different deleterious DNA lesions, it is unsurprising that the mechanisms by which it induces cell death are complicated. Despite ALX treatment causing cell cycle arrest in S and G2 phases of the cycle, it is clear that checkpoint slippage can occur and cells enter mitosis, most probably with unrepaired DNA DSBs, underreplicated DNA and/or catenated sister chromatids. As a result a major cause of cell death in epithelial tumour lines is through mitotic catastrophe after treatment with low doses of ALX. On this basis, since mitotic catastrophe does not require a functional ATM-p53 axis, tumour cells normally resistant to most conventional chemotherapeutic agents, due to mutations in this pathway, should be sensitive to killing by ALX. However, we did observe that ALX, at low dose, could induce apoptosis in HeLa cells, albeit to a low level, as judged by the partial PARP1 cleavage. Although it should be noted that this did not coincide with Pro-caspase 3 nor Lamin B1 cleavage, indicating the possible activation of a noncanonical apoptotic pathway. In this respect, it has been observed that cells undergoing a prolonged block in mitosis can induce a p53-dependent apoptotic mode of cell death following slippage into the subsequent G1 phase of the cell cycle. 23 Consistent with this, we observed that ALX can induce the stabilisation of p53, although it only appeared to be transcriptionally competent at later times during the DDR, probably linked with the generation of DSBs. It is therefore conceivable that ALX can induce cell death through either mitotic catastrophe and/or apoptosis. In keeping with this, ALX robustly induces apoptosis in the lymphoid tumour cells although this did not appear to require p53. Taken together our observations indicate that ALX can induce cell death through multiple different pathways in a variety of cell types Figure 10 . A possible mechanism for the mode of action of ALX. ALX inhibits TOP2 complexes present at a replication fork that results in the generation of a DNA double strand break (DSB). The binding of ALX to TOP2 may promote its ability to alkylate DNA in close proximity to a replication fork. The combination of a DSB and localised DNA alkylation is likely to result in fork stalling and activation of the ATR-dependent cell cycle checkpoint pathway. Following a prolonged growth arrest, a significant proportion of cells bypass the checkpoint and either enter into mitosis with unrepaired DNA damage that triggers mitotic catastrophe or activate p53-independent apoptosis. In cells lacking an intact ATR-Chk1 pathway or undergoing replication stress, an increased number of stalled/damaged replication forks collapse resulting in the activation DNA-PK. It is possible that attempted repair of a collapsed replication fork or TOP2-associated DSB by DNA-PK-dependent repair pathways produces deleterious DNA structures that exacerbate abortive mitosis.
independently of key regulators of the DDR known to be associated with treatment resistance.
Since ATM and TP53 are commonly mutated in lymphoid tumours and this is associated with increased disease progression and treatment resistance, to ascertain whether ALX could be used as an effective chemotherapeutic agent in vivo, to target these tumours, we used T-ALL xenografts as a model for treating lymphoid tumour cells with and without TP53 mutations. In vitro, ALX was able to induce a robust DDR and a significant amount of cell death in all three T-ALL tumour cell lines to a similar degree irrespective of TP53 status. Consistent with this, we observed that ALX was able to significantly reduce the tumour load in mice engrafted with any of the three T-ALL cell lines tested. Moreover, similar observations were seen in mice engrafted with a patientderived, primary T-ALL tumour.
In summary, we propose that ALX, through its ability to activate different pathways of the DDR and to induce cell death by mitotic catastrophe and/or apoptosis, represents a novel therapeutic agent with a clinical potential to treat resistant/relapsed tumours harbouring mutations in DDR genes.
MATERIALS AND METHODS
Cell lines
The human cell lines used in this study are detailed in Supplementary  Table S1 . Drug treatments ALX 9 and ZP275 were dissolved in dimethylsulphoxide and routinely added to cells to give a final concentration of 50 nM in the culture medium. For experiments examining cell killing, ALX concentrations of 150 and 500 nM were used. Cisplatin (Sigma, Dorset, UK) was used at a concentration of 10 μg/ml. The ATM inhibitors, KU-55933 (Merck, Watford, UK) or KU60019 (Tocris, Oxford, UK) were used at 10 μM, the DNA-PK inhibitor, NU7441 (Tocris) was used at 10 μM and the ATR inhibitor, VE-821 (Selleckchem, Newmarket, UK) was used at 5 μM. 4-hydroxy-tamoxifen (Sigma, Dorset, UK) was used at 334 nM. siRNA treatment Smart-pools (Thermo Loughborough, UK) of siRNA were used to reduce expression of MSH2, Mre11, TOP2α and TOP2β. siRNA (0.4 nmoles) was transfected into cells (4 × 10 5 ) using Oligofectamine (Invitrogen, Paisley, UK). Experiments were performed 72 h later.
Quantification of autophagy
HEK293A cells, expressing green fluorescent protein-LC3 33 were cultured in Dulbecco's modified Eagle's medium/10% foetal calf serum and this served as full media. Earle's balanced salt solution (EBSS) was used as a starvation medium. HEK293A cells were seeded onto glass coverslips, 24 h later ALX was added to the media and the cells were left for 24 h. Starvation was induced in EBSS for the final 4 h where indicated. Cells were fixed with paraformaldehyde and mounted on glass slides. Immunofluorescence microscopy was used to capture multiple random fields of cells and green fluorescent protein-LC3-labelled structures counted.
